Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

  Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver
  Disease and Fibrosis at AASLD 2012

Business Wire

NORCROSS, Ga. -- November 12, 2012

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today presented
new preclinical data on the mechanism of action of GR-MD-02 at the American
Association for the Study of Liver Disease (AASLD) Annual Meeting in Boston,
MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the
treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease.
These new data help to further explain the mechanism of action of GR-MD-02,
showing that this galectin inhibitor affects multiple pathways involved with
both the prevention and reversal of fibrosis in NASH pathology.

“The data presented at AASLD further elucidate the mechanism of how galectin
inhibition affects liver fibrosis in preclinical models of disease, resulting
in the prevention and reversal of fibrosis,” said Peter G. Traber, MD,
President, Chief Executive Officer and Chief Medical Officer, Galectin
Therapeutics. “As we continue to advance GR-MD-02 for the treatment of NASH
with advanced fibrosis, we are hopeful that galectin inhibition could provide
patients with a novel treatment option, where liver transplantation is
currently the only therapy available. GR-MD-02 is expected to enter the clinic
in the first quarter of 2013.”

The presentation, entitled “Galectin-3 targeting drugs inhibit multiple
pathological pathways leading to improvement of non-alcoholic steatohepatitis
(NASH)”, was authored by Peter G. Traber and Eliezer Zomer. As previously
demonstrated, GR-MD-02 treatment in a mouse model of NASH resulted in marked
improvement in liver histology with significant reduction in steatosis,
ballooning and inflammation, as well as fibrosis, determined by Sirius red
staining. This disease improvement upon treatment with GR-MD-02 was seen when
animals were treated early in disease (disease prevention) or after fibrosis
had been established (disease reversal).

The new data show that Galectin-3 protein expression was markedly increased in
animals with NASH, and those levels were dramatically reduced to barely
detectable levels following treatment with GR-MD-02. Elevated expression of
iNOS, an important inflammatory mediator, and CD36, a scavenger receptor
involved in the pathogenesis of NASH, were markedly reduced following
treatment with GR-MD-02. Alpha-smooth muscle actin, a marker used to identify
activated cells that cause liver fibrosis, showed increased numbers of cells
in control livers, which was markedly reduced in livers treated with GR-MD-02.
Together, these data suggest that GR-MD-02 works to prevent or reverse
fibrosis in NASH by reducing galectin-3, which is associated with multiple
pathogenic effects.

About NASH

NASH is a common disease of the liver, affecting 9 to 15 million people in the
United States. NASH is characterized by the presence of fat in the liver along
with inflammation and damage in people who drink little or no alcohol. Over
time, patients with NASH can develop fibrosis, or scarring of the liver, that
can lead to cirrhosis, a severe liver disease where transplantation is the
only current treatment available.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.


Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
Press spacebar to pause and continue. Press esc to stop.